The Gallipoli Medical Research Foundation collaborates on research projects with institutes and universities around the world.

We are fortunate to have collaborations and affiliations with a number of researchers, GP’s and specialists.

For a full list of all current clinical trials click here

Dr. Victoria Atkinson

Dr. Victoria Atkinson is a Senior Staff Specialist Medical Oncologist at the Princess Alexandra Hospital since 2007 and Visiting Medical Oncologist at Greenslopes Private Hospital since 2011.

Her undergraduate training was undertaken at the University of Queensland and she completed her FRACP in Medical Oncology in 2006. Her tumour interests include Melanoma and Gastro-intestinal tumours. Dr. Atkinson holds an appointment as an Associate Professor (School of Clinical Medicine) with the University of Queensland and is involved in the teaching and clinical examination of medical students as well as the supervision of advanced trainees in Medical Oncology.

She is on the executive board of the Australian and New Zealand Melanoma Trials Group and on the board of Melanoma Patients Australia.

Dr. Atkinson collaborates with the Gallipoli Medical Research Foundation to bring cutting edge clinical trials to her patients.

Currently open and recruiting trials as of 20/3/18

  • COMBI-I: A randomised Phase III study comparing the combination of PDR001 , Dabrafenib and Trametinib  versus Placebo, Dabrafenib and Trametinib in patients with unresectable or metastatic BRAF V600 mutant melanoma.
  • CO39721-Cobimetinib plus Atezolizumab in patients with advanced melanoma whose melanoma has worsened during or after treatment with previous immunotherapy and Atezolizumab monotherapy in Untreated Melanoma
  • CA0170-055:  A Phase II/III study of BMS-986205 combined with Nivolumab versus Nivolumab in patients with unresectable metastatic melanoma.
  • CA224-020: (Part D) A Phase1/2a Dose escalation and cohort expansion study of the safety, tolerability and Efficacy of the Anti-LAG3 monoclonal antibody BMS986016 administered alone and in combination with the Anti-PD1 monoclonal antibody Nivolumab in advanced solid tumours.
  • KEYNOTE-022- A study to investigate MK-3475 (pembrolizamab) in combination with trametinib and dabrafenib in patients with advanced melanoma.
  • ILLUMINATE 301 – A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma


Dr Pretoria Bilinski

Dr Pretoria Bilinski is a medical oncologist and palliative care physician. She attends one campus only, that is Greenslopes Private Hospital.

Her private rooms are located in the Ramsay Specialist Centre.

Her undergraduate training was undertaken at the University of Queensland. She has two Masters degrees, one in Palliative Care (from Flinders University) and the other in Health Administration (from university of NSW).

Her tumour interests include prostate, renal, bladder, breast, lung, and pancreatic tumours. She is a local college examiner for the RACP.

Her current trial as of 13/03/2018:

  • PROfound: a phase III open labelled randomized study Olaparib vs Enza or Abi in metastatic prostate cancer patient with HRR gene mutations.


Dr Warren Joubert

Dr Warren Joubert graduated from the University of Witwatersrand, South Africa in 1995. He completed his Fellowship with the Royal Australasian College of Physicians and training as a Medical Oncologist at the Princess Alexandra Hospital in Brisbane in 2006 having previously trained in Auckland, New Zealand and worked at the Royal Free Hospital in London.

He started working as a full-time staff specialist in medical oncology at the Princess Alexandra Hospital in 2007 where he is now a senior staff specialist in Medical Oncology. Warren began private practice at Greenslopes Hospital in early 2010.

Warren’s main interests are in gastro-intestinal cancer, including colo-rectal and pancreatic cancer; uro-genital cancer and sarcoma oncology. He also has an interest in neuroendocrine tumours and initiated the neuroendocrine multi-disciplinary meeting at the Princess Alexandra Hospital. He is a member of the Australasian Gastro-intestinal Trials Group and board member of the Australasian Sarcoma Study Group.

He is involved as a principal or associate investigator on a number of clinical trials in gastro-intestinal, breast and uro-genital cancer and in melanoma and sarcoma.

Warren aims to deliver personalised, evidence-based therapies to his patients with cancer and adopts a holistic approach to the care of his patients and their family members.

Currently recruiting:

  • NCAGN-1876-201 A Clinical trial with the purpose to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Ongoing/Past trials:

  • EMR100070-007  (JAVELIN Gastric 100)  Avelumab in First-Line Maintenance Gastric Cancer.
  • MK3475-059  (KEYNOTE-059) A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
  • AGITG-AG0111PS GAP: Phase II gemcitabine and nab-paclitaxel for resectable pancreas cancer


Dr Luke Hourigan

Dr Luke Hourigan is an Associate Professor of Medicine at the University of Queensland. He is an Interventional Gastroenterologist with a private practice based at Greenslopes Private Hospital in Brisbane. He is also the Clinical Director of Endoscopy at Princess Alexandra Hospital. In 2015, Dr Hourigan received a Cyril Gilbert Testimonal Fund Grant from the Gallipoli Medical Research Foundation. With this funding, Dr Hourigan is conducting a trial study exploring new endoscopic techniqes to reduce the risk of the recurrence of large bowel polyps (pre-cancerous lesions) after removal at colonoscopy.



Our Team

  • Darrell
    Director of Research & Head of Liver Research Unit

    Professor Darrell Crawford

    View full profile